Showing results (601-610 of 921) with videos related to
Sort By:
Pageof 93
The Journal of Antimicrobial Chemotherapy|June 25, 1999
Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitisF Trostdorf, R R Reinert, H Schmidt, et al.Glycobiology|March 25, 1999
Differential expression of alpha2-6 sialylated polylactosamine structures by human B and T cellsB Kniep, K Schäkel, M Nimtz, et al.Neuroscience|June 16, 2010
Cellular prion protein overexpression disturbs cellular homeostasis in SH-SY5Y neuroblastoma cells but does not alter p53 expression: a proteomic studyE Weiss, S Ramljak, A R Asif, et al.Drug and Alcohol Dependence|July 1, 2021
Decreased cocaine demand following contingency management treatmentJin H Yoon, Robert Suchting, Constanza de Dios, et al.Behavioural Pharmacology|January 4, 2021
Initial development of a brief assessment of cocaine demandJin H Yoon, Constanza de Dios, Robert Suchting, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1986
17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humansA Höck, G Spohr, M Schmitz, et al.Drug and Alcohol Dependence|January 16, 2014
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexoneJoy M Schmitz, Charles E Green, Angela L Stotts, et al.Child Abuse & Neglect|September 3, 2023
LGBTQ+ identity-related abuse during childhood and associations with depression and suicide behavior: Role of adulthood cisheterosexism and expressive suppressionRuby Charak, Ines Cano-Gonzalez, Roman Ronzon-Tirado, et al.British Journal of Cancer|December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesR Bartsch, A Berghoff, U Pluschnig, et al.The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.Pageof 93